Cited by 122Medicinal Plant ResearchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants

Open access
Nair, M.S., Huang, Y., Fidock, D.A., Polyak, S.J., Wagoner, J., Towler, M.J., Weathers, P.J.·2021·Journal of Ethnopharmacology

Published version of a preprint

Abstract

Ethnopharmacological relevance Artemisia annua L. has been used for millennia in Southeast Asia to treat "fever". Many infectious microbial and viral diseases have been shown to respond to A. annua and communities around the world use the plant as a medicinal tea, especially for treating malaria.Aim of the study SARS-CoV-2 (the cause of Covid-19) globally has infected and killed millions of people. Because of the broad-spectrum antiviral activity of artemisinin that includes blockade of SARS-CoV-1, we queried whether A. annua suppressed SARS-CoV-2.Materials and methods Using Vero E6 and Calu-3 cells, we measured anti SARS-CoV-2 activity against fully infectious virus of dried leaf extracts of seven cultivars of A. annua sourced from four continents. IC50s were calculated and defined as the concentrations that inhibited viral replication by 50%; CC50s were also calculated and defined as the concentrations that kill 50% of cells.Results Hot-water leaf extracts based on artemisinin, total flavonoids, or dry leaf mass showed antiviral activity with IC 50 values of 0.1-8.7 μM, 0.01-0.14 μg, and 23.4-57.4 μg, respectively. Antiviral efficacy did not correlate with artemisinin or total flavonoid contents of the extracts. One dried leaf sample was >12 years old, yet its hot-water extract was still found to be active. The UK and South African variants, B1.1.7 and B1.351, were similarly inhibited. While all hot water extracts were effective, concentrations of artemisinin and total flavonoids varied by nearly 100-fold in the extracts. Artemisinin alone showed an estimated IC 50 of about 70 μM, and the clinically used artemisinin derivatives artesunate, artemether, and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations. In contrast, the antimalarial drug amodiaquine had an IC 50 = 5.8 μM. Extracts had minimal effects on infection of Vero E6 or Calu-3 cells by a reporter virus pseudotyped by the SARS-CoV-2 spike protein. There was no cytotoxicity within an order of magnitude above the antiviral IC 90 values.Conclusions A. annua extracts inhibit SARS-CoV-2 infection, and the active component(s) in the extracts is likely something besides artemisinin or a combination of components that block virus infection at a step downstream of virus entry. Further studies will determine in vivo efficacy to assess whether A. annua might provide a cost-effective therapeutic to treat SARS-CoV-2 infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jep.2021.114016

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Artemisinin and its derivatives are effective against various types of cancers and tumors, some viruses including SARS-CoV-2, tuberculosis, and many other parasites including Schistosoma sp., Leishmania sp., Borrelia burgdorferi, and Trypanosoma sp.

    “Artemisinin and its derivatives are not only effective against malaria, but also against various types of cancers and tumors (Efferth 2017), some viruses (Efferth et al. 2008; Efferth 2018) including SARS-CoV-2 (Nair et al. 2021), tuberculosis (Martini et al. 2020; Zheng et al. 2017), and many other parasites including Schistosoma sp. (Munyangi et al. 2018), Leishmania sp. (Mesa et al. 2017), Borr”

    From Enhancing artemisinin content in and delivery from Artemisia annua: a review of alternative, classical, and transgenic approaches (2021) · cites this paper as Nair et al. 2021

    Nair et al. is cited for the SARS-CoV-2 part of the sentence, not for cancer, tuberculosis, or the listed parasites. Its Results (‘Activity of antimalarials’) report in vitro activity for artemisinin and artemether, but artesunate and dihydroartemisinin were inactive at tested concentrations. The paper does not establish that artemisinin and its derivatives are effective against SARS-CoV-2 in patients. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Nair, M. S., Huang, Y., Fidock, D. A., Polyak, S. J., Wagoner, J., Towler, M. J., & Weathers, P. J.
Affiliations
  • Aaron Diamond AIDS Research Center (US)
  • Columbia University Irving Medical Center (US)
  • University of Washington (US)
  • Worcester Polytechnic Institute (US)
Corresponding author
  • Nair, M.S.
  • Weathers, P.J.
Venue
Journal of Ethnopharmacology
Publisher
Elsevier BV
Published
2021-06
Volume
274
Pages
114016
ISSN
0378-8741 (ISSN-L)
OpenAlex
W3134666776
Cited by
122
References
42
Citations by year
2026: 7 · 2025: 12 · 2024: 19 · 2023: 29 · 2022: 40 · 2021: 15
FWCI
15.46
Type
journal article
Language
en
Open access
Locations
  • Journal of Ethnopharmacology (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Medicinal Plant Research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
Artemisia annua, SARS-CoV-2, COVID-19 pandemic, artemisinin, antiviral activity, plant extracts, viral replication inhibition, SARS-CoV-2 variants, Alpha variant, Beta variant, flavonoids, artemisinin derivatives, amodiaquine, cytotoxicity, medicinal plants
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Animals, Antiviral Agents, Cell Line, Chlorocebus aethiops, Flavonoids, Humans, Plant Extracts, Vero Cells, Virus Replication, Plant Leaves, Artemisia annua, Artemisinins, Cell Line, Tumor, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review